238 related articles for article (PubMed ID: 37110523)
1. Inhibitory Potential of the
Mir SA; Madkhali Y; Firoz A; Al Othaim A; Alturaiki W; Almalki SG; Algarni A; Alsagaby SA
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110523
[TBL] [Abstract][Full Text] [Related]
2. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
3. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
4. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
7. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
8. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
9. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
10.
Mohapatra PK; Chopdar KS; Dash GC; Mohanty AK; Raval MK
J Biomol Struct Dyn; 2023 Feb; 41(2):435-444. PubMed ID: 34821198
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
Mubashir N; Fatima R; Naeem S
Curr Comput Aided Drug Des; 2020; 16(4):420-434. PubMed ID: 32883197
[TBL] [Abstract][Full Text] [Related]
12. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
13. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Rhodes JM; Mato AR
Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
15. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
17. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
19. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
Sharif-Askari B; Doyon D; Paliouras M; Aloyz R
Sci Rep; 2019 Jul; 9(1):11069. PubMed ID: 31363127
[TBL] [Abstract][Full Text] [Related]
20. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
